Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Avidity Biosciences with an Overweight rating and $60 price target. Avidity has a strong management team, a proven platform, a robust pipeline, and what appears to be a blockbuster product in del-desiran for myotonic dystrophy type 1, making up “the complete package,” the analyst tells investors in a research note. The firm does not anticipate delays from a partial FDA clinical hold on the HARBOR trial stemming a prior safety observation and expects enrollment to be brisk.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RNA:
- Dyne Therapeutics price target raised to $37 from $33 at Guggenheim
- Avidity Biosciences price target raised to $33 from $23 at Chardan
- Avidity Biosciences Reveals Promising Trial Results and Phase 3 Plans
- Avidity Biosciences announces ‘positive’ data from MARINA-OLE trial
- Avidity Biosciences Launches Major Stock and Warrants Placement
